Investigational Drug Details
| Drug ID: | D099 |
| Drug Name: | Norepinephrine |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB00368 |
| DrugBank Description: | Precursor of epinephrine that is secreted by the adrenal medulla and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers and of the diffuse projection system in the brain arising from the locus ceruleus. It is also found in plants and is used pharmacologically as a sympathomimetic. |
| PubChem ID: | 439260 |
| CasNo: | 51-41-2 |
| Repositioning for NAFLD: | Yes |
| SMILES: | NC[C@H](O)C1=CC(O)=C(O)C=C1 |
| Structure: |
|
| InChiKey: | SFLSHLFXELFNJZ-QMMMGPOBSA-N |
| Molecular Weight: | 169.1778 |
| DrugBank Targets: | Alpha-1A adrenergic receptor; Alpha-1B adrenergic receptor; Alpha-1D adrenergic receptor; Alpha-2A adrenergic receptor; Alpha-2B adrenergic receptor; Alpha-2C adrenergic receptor; Beta-1 adrenergic receptor; Beta-2 adrenergic receptor; Beta-3 adrenergic receptor; Phenylalanine-4-hydroxylase; Synaptic vesicular amine transporter; Chromaffin granule amine transporter |
| DrugBank MoA: | Norepinephrine functions as a peripheral vasoconstrictor by acting on alpha-adrenergic receptors. It is also an inotropic stimulator of the heart and dilator of coronary arteries as a result of it's activity at the beta-adrenergic receptors. |
| DrugBank Pharmacology: | Noradrenaline acts on both alpha-1 and alpha-2 adrenergic receptors to cause vasoconstriction. Its effect in-vitro is often limited to the increasing of blood pressure through antagonising alpha-1 and alpha-2 receptors and causing a resultant increase in systemic vascular resistance. |
| DrugBank Indication: | Mainly used to treat patients in vasodilatory shock states such as septic shock and neurogenic shock and has shown a survival benefit over dopamine. Also used as a vasopressor medication for patients with critical hypotension. |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L1718 | NCT00077597 | PHASE3 | COMPLETED | NO | 2004-02 | 2016-11-02 | Details |
| L2100 | NCT01676220 | PHASE3 | COMPLETED | YES | 2012-08 | 2015-06-24 | Details |
| L3145 | NCT00600626 | PHASE3 | COMPLETED | NO | 2004-01 | 2017-01-06 | Details |
| L3549 | NCT00427401 | PHASE2 | TERMINATED | NO | 2007-02 | 2008-09-29 | Details |
| L3639 | NCT01614769 | PHASE1 | COMPLETED | YES | 2012-07-18 | 2018-08-16 | Details |
| L3880 | NCT00013910 | PHASE1 | COMPLETED | NO | 2005-06-24 | Details | |
| L7000 | NCT01552005 | COMPLETED | NO | 2012-05 | 2016-06-07 | Details | |
| L7248 | NCT03867851 | PHASE2 | TERMINATED | NO | 2021-02-08 | 2024-05-16 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name | |
|---|---|---|---|---|---|---|---|
| T03 | Angiotensin-converting enzyme | ACE | INHIBITOR | Target is a single protein chain | P12821 | ACE_HUMAN | Details |
| T06 | Sulfonylurea receptor 1 | ABCC8 | Target is a single protein chain | Q09428 | ABCC8_HUMAN | Details | |
| T47 | Sialin | SLC17A5 | Target is a single protein chain | Q9NRA2 | SLC17A5_HUMAN | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|